Paper32150405
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Diab S and 2 others. J Med Chem, 2020. Cited by 70 papers, by iCite.
Cite this record
ConductScience Library. CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? Papers, record 32150405. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32150405
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cyclin-Dependent Kinases | Major topic |
| Neoplasms | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Animals | |
| Apoptosis | |
| Cell Cycle Checkpoints | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Humans | |
| Cyclin-Dependent Kinase-Activating Kinase |
Source PubMed
Cited by40
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 70 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42635915 | Targeting CDK7 to overcome hypomethylating agent resistance in acute myeloid leukemia. | Blood Res | 2026 | https://conductscience.org/library/papers/42635915 | PubMed |
| 42209292 | Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/42209292 | PubMed |
| 41575477 | Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules. | Mol Divers | 2026 | https://conductscience.org/library/papers/41575477 | PubMed |
| 41428738 | CDK7-CDK11 axis in spliceosome regulation and pre-mRNA splicing. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/41428738 | PubMed |
| 41188290 | Transcriptome-conditioned molecule generation via gene interaction-aware fragment modeling with a GPT-based architecture. | Sci Rep | 2025 | https://conductscience.org/library/papers/41188290 | PubMed |
| 41158223 | Recent advances in development of CDK7 inhibitors and their clinical trials: a narrative review. | Transl Cancer Res | 2025 | https://conductscience.org/library/papers/41158223 | PubMed |
| 41092317 | Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer. | J Natl Cancer Inst | 2026 | https://conductscience.org/library/papers/41092317 | PubMed |
| 40949156 | Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40949156 | PubMed |
| 40853714 | Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models. | ChemMedChem | 2025 | https://conductscience.org/library/papers/40853714 | PubMed |
| 39588561 | Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor-Positive Triple-Negative Breast Cancer by Inhibiting c-MYC-mediated Tumorigenesis. | Mol Cancer Ther | 2025 | https://conductscience.org/library/papers/39588561 | PubMed |
| 39414519 | Emerging roles of cyclin-dependent kinase 7 in health and diseases. | Trends Mol Med | 2025 | https://conductscience.org/library/papers/39414519 | PubMed |
| 39140066 | Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors. | ACS Med Chem Lett | 2024 | https://conductscience.org/library/papers/39140066 | PubMed |
| 39023263 | Cimicifugin, a broad-spectrum inhibitor of Theileria annulata and Plasmodium falciparum CDK7. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/39023263 | PubMed |
| 39004018 | Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7). | Eur J Med Chem | 2024 | https://conductscience.org/library/papers/39004018 | PubMed |
| 38983782 | Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside. | EXCLI J | 2024 | https://conductscience.org/library/papers/38983782 | PubMed |
| 38892310 | Ibulocydine Inhibits Migration and Invasion of TNBC Cells via MMP-9 Regulation. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892310 | PubMed |
| 38872861 | Cancer research in Lebanon: Scope of the most recent publications of an academic institution (Review). | Oncol Lett | 2024 | https://conductscience.org/library/papers/38872861 | PubMed |
| 38845825 | Exploring isoindolin-1-ones as potential CDK7 inhibitors using cheminformatic tools. | In Silico Pharmacol | 2024 | https://conductscience.org/library/papers/38845825 | PubMed |
| 38748374 | Computer-aided analysis of radiological images for cancer diagnosis: performance analysis on benchmark datasets, challenges, and directions. | EJNMMI Rep | 2024 | https://conductscience.org/library/papers/38748374 | PubMed |
| 38355840 | Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. | Br J Cancer | 2024 | https://conductscience.org/library/papers/38355840 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CDK7 | 1022 | PubTator's text mining | https://conductscience.org/library/genes/1022 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32150405
GET https://conductscience.org/api/papers/v1/32150405/cited_by?page=2